In patients with left-sided infective endocarditis a clinical response-tailored antibiotic strategy shortened antibiotic duration by two weeks compared with standard therapy, with no major safety ...

The Fifth Universal Definition of Myocardial Infarction (MI) released on behalf of a joint task force from the ACC, European Society of Cardiology (ESC), American Heart Association (AHA) and World ...

Implantation of an ICD did not significantly reduce sudden cardiac death (SCD) or hemodynamically significant ventricular arrhythmia (HSVA) compared with an implantable loop recorder (ILR) in patients ...

Silent atherosclerosis is detectable using imaging in early adulthood, with age- and sex-associated increases in prevalence across arterial territories and significant increases in plaque volume, ...

In patients with atrial fibrillation (AFib) at intermediate risk for stroke, DOAC therapy resulted in a lower risk of stroke, systemic embolism, major bleeding or death from cardiovascular causes at ...

Pacibekitug, a novel, long-acting monoclonal antibody that targets interleukin-6, produced sustained reductions in inflammatory markers in patients with chronic kidney disease (CKD) and at high ...

Tiny fragments of plastic have become ubiquitous in our environment and our bodies. Higher exposure to these microplastics, which can be inadvertently consumed or inhaled, is associated with a ...

The newest clinical guideline released by the ACC and the American Heart Association (AHA) provides new and updated recommendations for preventing and optimally managing atrial fibrillation (AFib).

This page features ACC's coverage of the latest science from ESC Congress 2026, taking place August 28-31 in Munich.

It is a tremendous honor to serve as Chair of ACC's Women in Cardiology (WIC) Member Section Leadership Council. I am deeply grateful to the visionary leaders who have built this extraordinary ...

The proposed 2026 Medicare Physician Fee Schedule (PFS) includes a proposal to reduce the physician work relative value unit (RVU) for performing a left atrial appendage closure procedure (LAAO) from ...

The U.S. Food and Drug Administration (FDA) has approved the Sapien 3, Sapien 3 Ultra and Sapien 3 Ultra Resilia TAVR valves from Edwards Lifesciences to treat patients with asymptomatic severe aortic ...